Such findings highlight the importance and possible suitability of MUC16 as a CAR-T therapy target antigen; however, hurdles must be recognized and arduously overcome to better the therapeutic responses achieved in ovarian cancer patients. This evidence concerns the gene MUC16 and ovarian carcinoma.